Christopher W Murray

List of Publications by Year
in descending order

14 papers	1,419 citations	759233 12 h-index	1058476 14 g-index
14 all docs	14 docs citations	14 times ranked	1917 citing authors

#	Article	IF	Citations
1	Fragment-based drug discovery: opportunities for organic synthesis. RSC Medicinal Chemistry, 2021, 12, 321-329.	3.9	35
2	ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK. Molecular Cancer Therapeutics, 2021, 20, 1757-1768.	4.1	13
3	Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2. Journal of Medicinal Chemistry, 2021, 64, 12286-12303.	6.4	9
4	A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA. MedChemComm, 2019, 10, 1509-1511.	3.4	47
5	Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2. Journal of Medicinal Chemistry, 2018, 61, 4978-4992.	6.4	42
6	The Fragment Network: A Chemistry Recommendation Engine Built Using a Graph Database. Journal of Medicinal Chemistry, 2017, 60, 6440-6450.	6.4	33
7	Fragment-to-Lead Medicinal Chemistry Publications in 2015. Journal of Medicinal Chemistry, 2017, 60, 89-99.	6.4	47
8	Opportunity Knocks: Organic Chemistry for Fragmentâ€Based Drug Discovery (FBDD). Angewandte Chemie - International Edition, 2016, 55, 488-492.	13.8	151
9	Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. Journal of Medicinal Chemistry, 2016, 59, 8189-8206.	6.4	182
10	Efficient exploration of chemical space by fragment-based screening. Progress in Biophysics and Molecular Biology, 2014, 116, 82-91.	2.9	127
11	Experiences in fragment-based drug discovery. Trends in Pharmacological Sciences, 2012, 33, 224-232.	8.7	227
12	Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nature Chemical Biology, 2012, 8, 920-925.	8.0	103
13	Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. Journal of Medicinal Chemistry, 2010, 53, 5956-5969.	6.4	230
14	Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. Journal of Medicinal Chemistry, 2010, 53, 5942-5955.	6.4	173